Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies (Q50027343)

23 February 2018

title

Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies (English)

1 reference

23 February 2018

author name string

Paulina Nowakowska

1

1 reference

23 February 2018

Annette Romanski

2

1 reference

23 February 2018

Nicole Miller

3

1 reference

23 February 2018

Marcus Odendahl

4

1 reference

23 February 2018

Halvard Bonig

5

1 reference

23 February 2018

Congcong Zhang

6

1 reference

23 February 2018

Erhard Seifried

7

1 reference

23 February 2018

Winfried S Wels

8

1 reference

23 February 2018

Torsten Tonn

9

1 reference

23 February 2018

publication date

6 September 2017

1 reference

23 February 2018

Cancer Immunology, Immunotherapy

published in

1 reference

23 February 2018

volume

67

1 reference

23 February 2018

issue

1

1 reference

23 February 2018

page(s)

25-38

1 reference

23 February 2018

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Treatment of patients with advanced cancer with the natural killer cell line NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Engineered T cells for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Evidence that transferrin supports cell proliferation by supplying iron for DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Expression, purification, and characterization of recombinant human transferrin from rice (Oryza sativa L.).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

Current concepts in the diagnosis and management of cytokine release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2055-2

10.1007/S00262-017-2055-2

21 January 2018

Identifiers

DOI

1 reference

23 February 2018

1 reference

23 February 2018